SAN DIEGO--(BUSINESS WIRE)-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows:
Webcasts of the presentations at the Oppenheimer and Cantor conferences will be available on the Events and Presentations page of the Biocept website and will be archived for 90 days.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic. For more information, visitwww.biocept.com. Follow Biocept onFacebook,LinkedIn andTwitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005034/en/
Investors: Jody Cain, LHA Investor Relations Jcain@lhai.com, 310-691-7100
Media: Andrea Sampson, Sampson PR Groupasampson@sampsonprgroup.com, 562-304-0301
Source: Biocept